
|Articles|February 15, 2003
Foresighted
Novartis Ophthalmics and Valley Forge Pharmaceuticals Inc. have entered into a licensing agreement for a novel eye medication for myopia, which in phase II clinical trials reduced progression of the disease by 50% in the first 12 months of therapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
DAYBREAK: Tarcocimab, tabirafusp-ted noninferior to aflibercept in wet AMD
2
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
3
Retina Society 2026: Could statins reduce PVR risk after RD repair?
4
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
5












